BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30706224)

  • 1. ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T
    Wang M; Wu K; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1236-1237. PubMed ID: 30706224
    [No Abstract]   [Full Text] [Related]  

  • 2. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Mittendorf EA; King TA
    Ann Surg Oncol; 2019 May; 26(5):1173-1175. PubMed ID: 30798446
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
    Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
    Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M; Rosman M; Mylander C; Tafra L
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASO Author Reflections: The Changing Role of Gene Expression Profiling in ER+/HER2- Breast Cancer.
    van Steenhoven JEC; van Dalen T
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):800-801. PubMed ID: 31650304
    [No Abstract]   [Full Text] [Related]  

  • 8. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
    Nicolini A; Ferrari P; Duffy MJ
    Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
    Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
    Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer.
    O'Cearbhaill R; Gannon JM; Prichard RS; Walshe JM; McDermott E; Quinn CM
    Pathobiology; 2019; 86(2-3):77-82. PubMed ID: 30347405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
    Park MM; Ebel JJ; Zhao W; Zynger DL
    Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
    Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
    Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
    PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
    Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
    Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Vissio E; Metovic J; Osella-Abate S; Bertero L; Migliaretti G; Borella F; Benedetto C; Sapino A; Cassoni P; Castellano I
    Br J Cancer; 2020 Feb; 122(3):382-387. PubMed ID: 31780778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database.
    Wang M; Chen H; Wu K; Ding A; Zhang M; Zhang P
    Breast; 2018 Feb; 37():56-63. PubMed ID: 29100045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.